In study, we analysed the anti-cancer activity of CBL0137 in Myc-high triple-negative breast cancer models. RNA-Seq was performed on murine syngeneic 4T1.2 tumours following one week of CBL0137 treatment to delineate the effect of CBL0137 treatment on global transcriptome of 4T1.2 tumours.
The MYC proto-oncogene is upregulated in >60% of triple-negative breast cancers (TNBCs), it can directly promote tumor cell proliferation and its overexpression negatively regulates anti-tumor immune responses. For all these reasons, MYC has long been considered as a compelling therapeutic target. However, pharmacological inhibition of MYC function has proven difficult due to a lack of a drug-binding pocket. Here, we demonstrate that the potent abrogation of MYC gene transcription by the FACT complex inhibitor CBL0137 selectively induces immunogenic cell death and reduces proliferation in MYC-high but not in MYC-low BC cells in vitro. CBL0137 also significantly reduced the in vivo growth of primary tumors and brain metastasis in a human MYC-high BC model (MDA-MB-231). Moreover, CBL0137 inhibited the tumor growth of mouse 4T1.2 BC in immunocompetent mice by inhibiting the MYC pathway and inducing Type I interferon responses. Immune profiling of CBL0137-treated mice revealed significantly enhanced tumor-specific immune responses and increased proportions of tumor infiltrating effector CD8+ T cells, CD4+ T cells, and NK cells. CBL0137-induced immune activation also resulted in increased exhaustion of immune effector cells. In particular, NKG2A up-regulation on activated effector cells and of its ligand Qa-1b on tumors in vivo was identified as a possible immune evasive mechanism. Indeed, NKG2A blockade synergized with CBL0137 significantly inhibiting the in vivo growth of 4T1.2 tumors. Collectively, our findings provide the rationale supporting the exploitation of CBL0137-induced anti-tumor immunity in combination with NKG2A blockade to improve the treatment of TNBC expressing high levels of MYC.